A Study of the Long-term Safety of Sativex Use
A Long-term, Open Label, Safety and Tolerability Study of Cannabis Based Medicine Extract in Patients Who Have Participated in a GW Clinical Study Using Cannabis Based Medicine.
What it found
Results are posted in the registry, but without a statistical test of the main measure. See the numbers below.
What was tested
Treatment tested
- Nabiximols
Results by group
Incidence of Adverse Events as a Measure of Subject Safety.
Up to 1051 days
| Group | Value | Interval | Number analysed |
|---|---|---|---|
| GW-1000-02 | 477 participants | 507 |
Values as posted on ClinicalTrials.gov. Outcomes measured differently across trials are not directly comparable.
Safety
| Group | Participants at risk | Serious adverse events | Deaths |
|---|---|---|---|
| GW-1000-02 | 507 | 74 (14.6%) |
As posted on ClinicalTrials.gov. Serious adverse events include any serious health event during the trial, whether or not the treatment caused it.
What it measured
Main measures
Incidence of Adverse Events as a Measure of Subject Safety.
Up to 1051 days
Safety
Other measures (16)
Change From Parent Study Baseline in Spasticity 0-10 Numerical Rating Scale Score After 52 Weeks of Treatment.
0 - 52 weeks
SpasticityChange From Parent Study Baseline in Central Neuropathic Pain 0-10 Numerical Rating Scale Score at 52 Weeks of Treatment.
0 - 52 weeks.
PainChange From Parent Study Baseline in Neuropathic Pain 0-10 Numerical Rating Scale Score at 52 Weeks of Treatment in Multiple Sclerosis Subjects.
0 - 52 weeks.
PainChange From Parent Study Baseline in Pain 0-10 Numerical Rating Scale Score at 52 Weeks of Treatment.
0 - 52 weeks.
PainSubject Assessment of Benefit at the Last Study Visit in Those Experiencing Neuropathic Pain Due to Multiple Sclerosis.
Up to 1051 days
PainInvestigator Assessment of Benefit at the Last Study Visit in Those Experiencing Neuropathic Pain Due to Multiple Sclerosis.
Up to 1051 days
PainSubject Assessment of Benefit at the Last Study Visit in Those Experiencing Central Neuropathic Pain.
Up to 1051 days
PainInvestigator Assessment of Benefit at the Last Study Visit in Those Experiencing Central Neuropathic Pain.
Up to 1051days
PainSubject Assessment of Benefit at the Last Study Visit in Those Experiencing Pain.
Up to 1051
PainInvestigator Assessment of Benefit at the Last Study Visit in Those Experiencing Pain.
Up to 1051 days
Pain
Who could take part
MS (type not specified) · 18 and over
Show the full criteria
Inclusion criteria
* Willing and able to give informed consent. * Male or female aged 18 years or above. * Diagnosed with a condition categorised as one of the following: multiple sclerosis, spinal cord conditions, peripheral nerve injury or central nervous system damage associated with vascular, traumatic, infective, genetic or metabolic disease and whose symptom(s) were not wholly relieved by currently available therapy, prior to the previous study of GW-1000-02 or placebo. * Had participated in a GW clinical study using GW-1000-02 within the previous month. * Had shown tolerability to the study medication during the previous GW study. * Was expected, by the investigator, to gain clinical benefit from receiving long-term GW-1000-02. * Were willing, if female and of child bearing potential or male subjects with a partner of child bearing potential, to ensure that effective contraception was used during the study and for three months thereafter. * Had not used cannabinoids (cannabis, Marinol or Nabilone) for at least seven days before Visit 1 (the exception being GW-1000-02 given as study medication) and were willing to abstain from any use of cannabis during the study. * Recent (within seven days) haematology and blood chemistry that was normal or considered clinically acceptable in view of the subjects underlying condition. * Able (in the investigators opinion) and willing to comply with all study requirements. * Willing for the Home Office to be notified of his or her participation in the study. * Willing to allow his or her general practitioner and consultant, if appropriate, to be notified of participation in the study.
Exclusion criteria
* History of serious psychiatric illness, including schizophrenia, other psychotic illness or severe personality disorder other than depression associated with the underlying condition. * Known or strongly suspected of alcohol or substance abuse or considered by the investigator to have been at risk of alcohol or substance abuse. * Severe cardiovascular disorder, such as ischaemic heart disease, arrhythmias (other than well controlled atrial fibrillation), poorly controlled hypertension or severe heart failure. * History of epilepsy or convulsions. * Significant renal or hepatic impairment. * Terminally ill. * Any other significant disease or disorder which, in the opinion of the investigator, may have either put the subject at risk because of participation in the study, or may have influenced the result of the study, or the subject's ability to participate in the study. * Female subjects who were pregnant, lactating or planning pregnancy during the course of the study. * Regular levodopa (Sinemet, Sinemet Plus, Levodopa, L-dopa, Madopar, Benserazide) therapy within seven days of study entry. * Known or suspected hypersensitivity to cannabinoids or any of the excipients of the study medication. * Known or suspected adverse reaction to cannabinoids. * Donation of blood during the study. * Previous participation in this study.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
Subjects who had previously received GW-1000-02 in a GW study who opted to continue using it in the long-term were monitored for ongoing tolerability and evidence of clinical benefit.
Papers
Loading reviews and guidelines…
Related trials
- Cryoneurolysis to treat pain in the context of spasticity
Phase 4 · Ongoing (inferred)
Still running
- A Study to Investigate Arbaclofen ER Tablets for the Treatment of Spas
Phase 3 · Not yet recruiting
Still running
- Cannabis (THC vs. CBD) in Multiple Sclerosis
Phase 2 · Recruiting
Still running
- Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pa
Phase 2 · Recruiting
Still running
- Antibiotic strategy and asymptomatic bacteriuria in the context of int
Phase 3 · Ongoing
Still running
- A study to asses the effects of Nabiximols on spasticity associated wi
Phase 3 · Completed
No results found
History
Started
Feb 2002
Main results due
Dec 2004
Finished
Dec 2004
Results posted
Aug 2012